|
|
GUIDELINES
for
Minority Supplements to the NCI Institutional Clinical Oncology
Research Career Development Program (K12S)
|
|
INTRODUCTION
The Comprehensive Minority Biomedical Branch (CMBB) of the National
Cancer Institute (NCI) has established a new strategy for increasing
the number of underrepresented minority individuals engaged in basic,
clinical and population-based biomedical cancer research. This strategy
is called the Continuing Umbrella of Research
Experiences (CURE) Program for underrepresented minority
populations. This program begins with introductory science experiences
at the high school student level and continues progressively and
selectively to the production of well-trained scientists conducting
independent cancer research (http://minorityopportunities.nci.nih.gov).
It is clear that the success of research designed to reduce the
disproportionate burden of cancer incidence and mortality in many
ethnic and racial groups will depend substantially on the presence
of a cadre of culturally sensitive, well-trained scientists from
these underrepresented populations.
The NCI invites NCI-supported Institutional Clinical Oncology Research
Career Development Program grantees (K12) to participate in the
CURE Program by submitting administrative supplements to
place promising underrepresented minority board eligible/certified
clinical oncologists in patient-oriented cancer research settings.
|
|
PURPOSE
The purpose of the K12 CURE supplement is to increase the
number of medical doctors and Oncology Registered Nurses with doctoral
degrees from underrepresented populations who are motivated and
properly trained to: (1) communicate and collaborate with basic/behavioral
research scientists in order to expedite the translation of basic/behavioral
information into patient oriented research; (2) perform independent
clinical research that develops and tests rational scientific hypotheses
based on fundamental and clinical research findings with the potential
for improving the medical care of cancer patients; and (3) design
and test innovative clinical protocols and manage all phases (i.e.,
pilot/Phase I, Phase II, Phase III) of clinical trials research.
For the purposes of this award, patient oriented research is defined
as research conducted with human subjects (or on material of human
origin such as tissues, specimens, and cognitive phenomena) for
which an investigator directly interacts with human subjects. This
area of research includes: (1) mechanisms of human disease;
(2) therapeutic interventions; (3) clinical trials; and (4) the
development of new technologies.
By providing research opportunities for underrepresented minorities
through supplements to ongoing K12 awards, it is anticipated that
the numbers of underrepresented individuals in the clinical oncology
field will increase significantly.
NIH recognizes the need to increase the number of underrepresented
minority scientists participating in biomedical and behavioral research.
The NCI is emphasizing the use of the administrative supplement
process to reach individuals from underrepresented populations interested
in cancer clinical research and interested in participating more
effectively in patient-oriented research. Using supplements to K12s
(PAR-00-063) rather than R01s will provide a far more efficient
way to place larger numbers of minority clinical oncologists in
these research environments.
|
|
ELIGIBILITY
Program
Any NCI-supported Institutional Clinical Oncology Research Development
Award (K12) grantee is eligible to apply for this supplement. These
supplements must be used for the sole purpose of including an individual
from an underrepresented population in the K12 program.
The CURE supplemental application must meet all of the eligibility
requirements and must describe a program that provides all of the
training and research career development opportunities for appointments
to the NCI Clinical Oncology Career Development Program stated in
PAR-00- 063 governing the current K12 award.
The CURE supplement is not intended to provide an alternative
means of supporting minority individuals who already receive support
from a research grant, a research training grant, a career development
award, or any other DHHS funding mechanism essentially duplicating
the provisions of the CURE supplement.
Individuals supported directly by the K12 program may not be concurrently
supported by a CURE supplement and may not be transferred
to a CURE supplement in order to increase the availability
of funds to the parent grant for other uses.
Clinician Candidates
For CMBB purposes, a person is an underrepresented minority if
he or she belongs to a particular ethnic and racial group that has
been determined by the grantee institution to be underrepresented
in cancer-related biomedical, behavioral, clinical or social science
research. Underrepresented individuals are not limited to racial
and ethnic minorities but can also include individuals, as selected
by the institution, as underrepresented as cancer researchers, e.g.,
first generation college graduates, the economically disadvantaged,
etc.
All candidates must be physicians holding the M.D. or D.O. degree,
or be oncology registered nurses with doctoral degrees, must have
completed residency, and must be board eligible. Candidates must
be able to spend a minimum of 75 percent of a full time professional
effort conducting research and research career development activities
including taking courses during the period of the award.
All clinician candidates must be U.S. citizens or non citizen nationals,
or must be lawfully admitted for permanent residence and possess
an Alien Registration Card I 551 or some verification of legal admission
as a permanent resident of the U.S. Non citizen nationals, although
not U.S. citizens, owe permanent allegiance to the U.S.; they usually
are born in the lands that are not states, but under U.S. sovereignty,
jurisdiction or administration. Foreign nationals and individuals
on temporary or student visas are not eligible.
Individuals NOT eligible for a CURE supplement include former
principal investigators on NIH research project grants (R01), FIRST
Awards (R29), sub-leaders of program projects (P01) or cancer center
(P30) grants, and the equivalent. Former principal investigators
of NIH Small Grants (R03) or Exploratory/Developmental Grants (R21)
remain eligible.
|
|
MECHANISM OF SUPPORT AND SPECIAL CONSIDERATIONS
The K12 CURE Program uses administrative supplements to
the K12 and provides up to five years of support per supplement.
In all cases, at the time of a K12 CURE supplement, the parent
K12 grant must have support remaining for at least one year. Planning,
direction and execution of the CURE supplement is the responsibility
of the Principal Investigator and the Advisory Committee on behalf
of the appointee. K12 CURE Supplements are not renewable.
K12 CURE supplements are administered under NIH Grants Policy
Statement (rev. 3/01). The competing supplements are not subject
to the Just-in-Time or the modular grant procedures. In future years,
the non-competing application process is not subject to the Streamlined
Non-competing Application Process (SNAP). Expanded Authorities are
in place, except that carry over of funds from one fiscal year to
the next requires NCI approval.
Support under the K12 CURE supplement program is not transferable
to another individual or transportable to another institution.
Allowable Costs
Clinician trainees may be provided salary up to $75,000 each year,
plus fringe benefits. The total salary requested must be based on
a full time, 12 month staff appointment. The actual salary must
be consistent both with the established salary structure at the
applicant institution and with salaries actually provided by the
institution from its own funds to other members with equivalent
qualifications, rank and responsibilities in the department concerned.
Supplementation of the NIH salary contribution up to a level that
is consistent with the institution=s salary scale are subject to
the same rules as for appointments directly to the K12 grant as
described in PAR -03-083. Candidates cannot receive concurrent salary
support from any other PHS award while being supported by the K12
program. Salaries for principal investigators, mentors, secretaries,
administrative assistants and other ancillary personnel are NOT
allowed.
Up to $30,000 in direct costs per trainee per year can be provided
for the following types of expenses: (a) research-related expenses,
such as supplies, equipment and technical personnel; (b) tuition,
fees and books related to career development; (c) travel to research
meetings or training; and (d) statistical services including personnel
and computer time. These costs must be specifically and directly
related to an individual trainee=s research activities. They cannot
be pooled and used for advertising, recruiting or other purposes
unrelated or indirectly related to the research activities of individual
trainees.
Facilities and administrative costs (formerly called indirect costs)
will be reimbursed at 8 percent of modified total direct costs.
|
|
SPECIFIC APPLICATION INSTRUCTIONS
The PHS 398 research grant application instructions and forms (rev.
5/01) at http://grants.nih.gov/grants/funding/phs398/phs398.html
are to be used in applying for these supplements. This version of
the PHS 398 is available in an interactive, searchable PDF format.
For further assistance contact GrantsInfo, Telephone 301/435-0714,
Email: GrantsInfo@nih.gov.
A request for a minority supplement to an NCI Institutional Clinical
Oncology Research Career Development Award may be submitted at any
time. In making requests, the grantee institution, on behalf of
the principal investigator of the parent grant, must submit the
request for supplemental funds to the NCI. Please note that this
procedure is different from the instructions in the PHS 398 application
package.
The original and three (3) legible copies of the supplemental application
should be sent to:
NCI Referral Officer
Division of Extramural Activities
National Cancer Institute
6116 Executive Blvd., Room 8109, MSC-8329
Rockville, MD 20852 (express courier)
Bethesda MD 20892-8329
All applications should follow the format provided below:
1. A completed face page with appropriate signatures using Form
Page 1 of PHS Form 398. Include the title and grant number of the
parent grant on line 1 and in line 2 write "K12 CURE Supplement."
2. PHS Form 398 budget pages (Form Pages 4 and 5) for the current
and future years.
3. A biographical sketch of the candidate (using the Biographical
Sketch Format Page) including background and achievements to date.
Include all licensures/board certifications of the candidate.
4. A biographical sketch of the laboratory and the clinical research
mentor(s) who will be responsible for the candidate. This sketch
should include a listing of current and pending research support,
preferably using the format of the OTHER SUPPORT pages in the PHS
Form 398.
5. A brief description of the planned training program for the
candidate. The plan must demonstrate that the candidate will be
fully incorporated into the K12 program, provided the same didactic,
laboratory and clinical research training opportunities as all other
K12 trainees, and able to meet all the requirements of the parent
K12 grant.
Specifically:
a. The program must provide the candidate with the patient oriented
research skills that deal directly with aspects of cancer detection,
diagnosis, prognosis, or treatment of cancer patients. It should
also provide the skills necessary for translating basic/ behavioral
cancer research results into clinical experiments, procedures,
and trials directly involving cancer patients in a clinical environment.
It will not be sufficient within the scope of this initiative
to use human cells and other clinical materials or animals in
an isolated basic laboratory setting as the total research development
program. Basic laboratory/behavioral research experience is essential,
but it must be properly integrated with patient oriented clinical
research, thereby affording the trainee actual experience in the
application of their own basic research to clinical research.
b.The Program should include Core Requirements that the candidate
is expected to complete in order to fulfill the objectives of
this training program. These requirements should include the following:
i. A didactic core component (e.g., formal courses in clinical
trial design, biostatistics, informed consent, Institutional
Review Boards; lecture series, seminars, and journal clubs)
based on the experience and needs of each candidate. In those
institutions with a Clinical Research Curriculum (K30) Award,
the didactic component should link with and incorporate the
new didactic programs developed through the K30 award.
ii. A clinical research core component that provides "hands
on"
experience (e.g., protocol development; preparation of IRB
applications; clinical trials management including patient
accrual and analysis of outcomes) in all aspects of clinical
trials.
iii. A basic research core component that adequately prepares
the trainee for communication, coordination, and collaboration
with basic scientists of clinical research activities; ideally this
would be linked to the core clinical research component.
When Human Subjects are involved in any aspect of the research,
all human subjects concerns must be addressed in the application.
These include Inclusion of Women and Minority in Research Involving
Human Subjects and the Inclusion of Children as Participants in
Research Involving Human Subjects. Guidelines may be found at http://grants.nih.gov/grants/guide/notice-files/not94-100.html
and http://grants.nih.gov/grants/guide/notice-files/not98-024.html.
The expectation of the NCI is that candidates will satisfy many
of the Core Requirements and that they will be provided with the
additional didactic and research experience over different periods
of time in order to fully meet the objectives of the K12 program.
|
|
REVIEW CONSIDERATIONS
The review of these supplemental applications will be conducted
by staff of the Comprehensive Minority Biomedical Branch and the
Cancer Training Branch of the NCI using the following review criteria:
1. The quality of the candidate's background and achievements at
his/her current level of career development.
2. The experience and qualifications of the laboratory and the
clinical research mentor(s).
3. The quality and breadth of the overall training and education
plan for the candidate, and appropriateness of the plan for the
stage of career development of the candidate.
4. The ability of the proposed training plan to fully incorporate
the candidate into the K12 program, providing the candidate with
the same opportunities for training and for meeting the requirements
of the K12 program as all the other K12 trainees.
|
|
FUNDING
Applications will compete for available funds with all other approved
applications. The applications will be rated and the one's ranked
the highest will be funded by the NCI. Funding decisions may take
approximately three to four months from receipt of a complete application.
It is expected that three to six positions will be funded each fiscal
year. Funding will be provided as an administrative supplement to
the parent grant; however continued funding for the supplement is
contingent upon successful progress of the minority investigator
and continued funding of the parent grant. Requests for future years
of support cannot exceed the parent grant project period.
NOTE
Candidates should be informed that their selection for this supplement
will automatically make them Members of the CURE Program of the
Comprehensive Minority Biomedical Branch of the National Cancer
Institute. This will entitle them to receive the CURE Newsletter
and have access to the multiple activities aimed at facilitating
the next steps of a career in cancer research. Information about
the CURE program of the NCI is published on the web at http://minorityopportunities.nci.nih.gov.
|
|
CONTINUATION OF SUPPORT
A progress report on the supplement must be submitted in the non-competing
continuation Institutional Clinical Oncology Research Career Development
Program application under a separate section entitled "K12
CURE" using the Non-Competing
Continuation for Minority Supplements to Institutional Clinical
Oncology Research Career Development Award (K12) form attached.
|
|
FINAL REPORT
At the end of the supplemental period, the Principal Investigator must provide
a final progress report which includes 1) name and ethnicity of
the appointee, 2) narrative description of the specific appointee's
research accomplishments, including all publications and clinical
protocols and 3) future career plans of the trainee. The original
of the final progress report should be sent to your Grants Management
Specialist with a copy to Ms. Bobby Rosenfeld at the address listed
below under the Inquiries section.
|
|
INQUIRIES
Direct inquiries regarding programmatic issues to:
Ms. Bobby Rosenfeld
Senior Program Analyst
Comprehensive Minority
Biomedical Branch
Office of Centers, Training and Resources
National Cancer Institute
6116 Executive Boulevard
Suite 7028, MSC 8350
Bethesda, MD 20892-8350
Rockville, MD 20852 (express/courier service)
Telephone: 301-496-7344
Fax: 301-402-4551
E-mail: rr63v@nih.gov
Direct inquiries regarding fiscal matters to:
Ms. Barbara A. Fisher
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 243
6120 Executive Boulevard
Bethesda, MD 20892
Telephone: 301-846-1015
FAX: 301-846-5720
E-mail: bf18m@nih.gov
|
|
|